Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Stoke Therapeutics, Inc. Stock Research

STOK

4.15USD-0.29(-6.53%)Market Closed
Watchlist

Market Summary

USD4.15-0.29
Market Closed
-6.53%

STOK Stock Price

STOK RSI Chart

STOK Valuation

Market Cap

183.4M

Price/Earnings (Trailing)

-1.75

Price/Sales (Trailing)

12.6

Price/Free Cashflow

-2.02

STOK Price/Sales (Trailing)

STOK Profitability

Return on Equity

-46.28%

Return on Assets

-35.12%

Free Cashflow Yield

-49.62%

STOK Fundamentals

STOK Revenue

Revenue Q/Q

57.65%

STOK Earnings

Earnings (TTM)

-105.0M

Earnings Y/Y

-24.35%

Earnings Q/Q

-35.97%

Price Action

52 Week Range

16.48
(Low)(High)

Last 7 days

-10.7%

Last 30 days

-20.4%

Last 90 days

-66.2%

Trailing 12 Months

-70.9%

STOK Financial Health

Current Ratio

8.57

STOK Investor Care

Shares Dilution (1Y)

12.60%

Diluted EPS (TTM)

-3.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for STOK

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-07-03
Ticho Barry
sold
-158,973
10.5982
-15,000
chief medical officer
2023-06-21
Allan Jonathan
sold
-26,252
13.4765
-1,948
general counsel & corp sec
2023-06-01
Ticho Barry
sold
-166,964
11.1309
-15,000
chief medical officer
2023-05-04
Ticho Barry
sold
-6,530
10.00
-653
chief medical officer
2023-05-03
Ticho Barry
sold
-250,366
10.1375
-24,697
chief medical officer
2023-05-02
Ticho Barry
sold
-55,133
10.0007
-5,513
chief medical officer
2023-05-01
Ticho Barry
sold
-249,767
10.0039
-24,967
chief medical officer
2023-03-27
Kaye Edward M. MD
acquired
12,000
0.6
20,000
ceo
2023-02-06
Ticho Barry
sold
-92,491
10.0153
-9,235
chief medical officer
2023-02-03
Ticho Barry
sold
-37,745
10.0306
-3,763
chief medical officer

1–10 of 50

Which funds bought or sold STOK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
reduced
-1.89
33,381
165,828
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-68.45
-1,578
1,062
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
20.29
98,791
283,417
-%
2023-08-16
Nuveen Asset Management, LLC
added
13.5
209,355
676,355
-%
2023-08-15
WELLS FARGO & COMPANY/MN
added
163
78,444
111,689
-%
2023-08-15
ALLIANCEBERNSTEIN L.P.
added
18.74
149,348
439,232
-%
2023-08-15
GOLDMAN SACHS GROUP INC
added
13.79
309,424
993,916
-%
2023-08-15
LAZARD ASSET MANAGEMENT LLC
added
48.84
14,000
29,000
-%
2023-08-14
STATE OF WISCONSIN INVESTMENT BOARD
added
27.39
355,375
923,439
-%
2023-08-14
GILDER GAGNON HOWE & CO LLC
reduced
-1.66
110,282
542,917
0.01%

1–10 of 46

Latest Funds Activity

Are funds buying STOK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own STOK
No. of Funds

Schedule 13G FIlings of Stoke Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
rtw investments, lp
9.8%
3,870,981
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
4.06%
1,602,045
SC 13G/A
Feb 03, 2023
redmile group, llc
9.7%
4,166,975
SC 13G/A
Jan 25, 2023
cowen financial products llc
1.89%
1,248,077
SC 13G/A
Feb 14, 2022
rtw investments, lp
9.9%
3,644,248
SC 13G/A
Feb 14, 2022
redmile group, llc
6.1%
2,246,668
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Jan 24, 2022
cowen financial products llc
5.09%
1,871,529
SC 13G
Jun 30, 2021
skorpios trust
-
6,905,121
SC 13D

Recent SEC filings of Stoke Therapeutics

View All Filings
Date Filed Form Type Document
Sep 20, 2023
3
Insider Trading
Sep 20, 2023
4
Insider Trading
Sep 20, 2023
8-K
Current Report
Sep 18, 2023
PRE 14A
PRE 14A
Sep 08, 2023
4
Insider Trading
Aug 07, 2023
10-Q
Quarterly Report
Aug 07, 2023
8-K
Current Report
Jul 25, 2023
8-K
Current Report
Jul 06, 2023
4
Insider Trading
Jun 23, 2023
4
Insider Trading

Peers (Alternatives to Stoke Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
271.1B
56.0B
2.30% 9.45%
31.22
4.84
-2.31% -31.27%
258.4B
1.8B
-1.67% 25.43%
-149.17
142.72
69.45% 14.65%
91.3B
9.5B
0.45% 22.78%
27.14
9.61
13.83% 5.33%
88.1B
12.7B
-1.51% 18.09%
20.49
6.95
-10.94% -24.40%
21.7B
1.2B
-7.00% -17.21%
-20.42
17.55
39.94% -8.44%
11.2B
1.0B
3.70% 3.57%
-12.29
11.11
20.15% -79.16%
10.5B
2.1B
-3.12% 8.08%
12.04
4.97
18.01% 38.16%
MID-CAP
3.0B
225.6M
0.04% -28.00%
-5.4
13.27
-2.11% 21.02%
2.9B
-
-10.01% 147.80%
-8.93
-
- -28.88%
2.6B
402.9M
-2.14% -20.15%
-3.63
6.49
20.50% -42.46%
2.1B
27.2M
-14.18% -57.07%
-2.89
78.22
- -14.43%
SMALL-CAP
3.1B
-
-2.94% -39.70%
-7.31
33.28
34.30% -149.91%
1.3B
302.9M
-16.58% -4.84%
11.18
4.26
77.72% 112.02%
289.9M
152.5M
-11.67% 38.41%
38.91
1.9
127.84% 103.41%
28.7M
-
1.35% 3552.08%
-0.62
-
- -31.51%

Stoke Therapeutics News

Best Stocks
Insider Stock Options and the Potential Value of Stoke Therapeutics.
Best Stocks,
10 hours ago
Best Stocks
InvestorsObserver
Seeking Alpha

Returns for STOK

Cumulative Returns on STOK

-50.9%


3-Year Cumulative Returns

Risks for STOK

What is the probability of a big loss on STOK?

94.6%


Probability that Stoke Therapeutics stock will be more than 20% underwater in next one year

87.5%


Probability that Stoke Therapeutics stock will be more than 30% underwater in next one year.

80.4%


Probability that Stoke Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does STOK drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Stoke Therapeutics was unfortunately bought at previous high price.

Drawdowns

Financials for Stoke Therapeutics

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q1
Revenue-100.0%-15.0012.0012.0012.0012.00
Operating Expenses1.9%12111911711110397.00
  S&GA Expenses0.3%40.0040.0039.0038.0037.0034.00
  R&D Expenses2.8%81.0079.0078.0073.0067.0063.00
Net Income-6.1%-104-98.96-101-99.86-96.35-93.66
Net Income Margin100.0%--6.80*-8.15*-8.20*-7.73*-7.81*
Free Cashflow100.0%--89.00-35.83-29.51-20.38-16.12
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Assets-8.8%257282256278301316239254264279298200210221229239246108
  Current Assets-8.9%246270244265289306229245260275294195206216226237244106
    Cash Equivalents0.9%19219011411368.0084.00145149169268287191202211222233243105
  Net PPE-4.7%6.007.007.007.006.005.004.003.003.003.003.003.003.003.003.002.002.001.00
Liabilities-1.8%67.0068.0071.0073.0077.0076.0021.0016.009.006.0012.007.007.006.004.005.005.002.00
  Current Liabilities-30.7%22.0032.0031.0029.0028.0023.0017.0012.008.006.0011.007.006.005.004.005.005.002.00
Shareholder's Equity-11.0%190214185204224240218238255272286193203214224234242105
  Retained Earnings-9.6%-350-319-297-271-245-220-196-171-149-127-110-95.72-82.03-69.07-58.03-47.87-39.27-25.71
  Additional Paid-In Capital1.3%541534483477471461414409404400396288285283282282281131
Shares Outstanding0.1%44.0044.0039.0039.0039.0037.0037.0037.0037.0037.0037.0033.0033.0033.0033.0013.003.001.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-2.2%-87,585-85,713-31,866-25,751-18,377-14,280-66,907-61,580-57,771-51,586-42,221-41,491-38,666-35,294-31,055-24,369-19,362-17,450-10,964-12,164-8,816
  Share Based Compensation2.5%24,36323,76622,85421,75020,43818,72716,45013,34410,5157,7125,7684,9003,8462,4951,9221,329638453240160162
Cashflow From Investing16.3%166,312142,985-45,882-56,575-129,103-212,004-76,426-88,313-83,318-644-1,050-1,529-1,843-2,154-1,634-1,148-1,081-918-925-2,064-652
Cashflow From Financing-6.9%45,57948,95646,40946,53746,51143,2451,284107,981108,246108,456108,1081,432-241150,028149,762239,349253,727137,452115,63953,51224,964

STOK Income Statement

2023-06-30
Consolidated statements of operations and comprehensive loss - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenue$ (2,481)$ 3,231$ 2,671$ 6,232
Operating expenses:    
Research and development20,55118,35840,18236,668
General and administrative10,23010,11120,44219,596
Total operating expenses30,78128,46960,62456,264
Loss from operations(33,262)(25,238)(57,953)(50,032)
Other income:    
Interest income (expense), net2,5675444,670648
Other income (expense), net41428483
Total other income2,6085864,754731
Net loss$ (30,654)$ (24,652)$ (53,199)$ (49,301)
Net loss per share, basic$ (0.69)$ (0.63)$ (1.23)$ (1.29)
Net loss per share, diluted$ (0.69)$ (0.63)$ (1.23)$ (1.29)
Weighted-average common shares outstanding, basic44,188,46439,258,35843,367,03238,358,936
Weighted-average common shares outstanding, diluted44,188,46439,258,35843,367,03238,358,936
Comprehensive loss:    
Net loss$ (30,654)$ (24,652)$ (53,199)$ (49,301)
Other comprehensive gain (loss):    
Unrealized gain (loss) on marketable securities219(592)796(1,108)
Total other comprehensive loss219(592)796(1,108)
Comprehensive loss$ (30,435)$ (25,244)$ (52,403)$ (50,409)

STOK Balance Sheet

2023-06-30
Consolidated balance sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 192,060$ 113,556
Marketable securities39,387116,039
Prepaid expenses10,95010,932
Other current assets3,6992,955
Interest receivable136588
Total current assets246,232244,070
Restricted cash569569
Operating lease right-of-use assets3,6464,753
Property and equipment, net6,4726,675
Total assets256,919256,067
Current liabilities:  
Accounts payable1,556766
Accrued and other current liabilities12,22215,748
Deferred revenue - current portion8,05914,880
Total current liabilities21,83731,394
Deferred revenue - net of current portion43,25836,856
Other long term liabilities1,6292,968
Total long term liabilities44,88739,824
Total liabilities66,72471,218
Commitments and contingencies (Note 6)
Stockholders’ equity  
Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 44,202,997 and 39,439,575 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively44
Additional paid-in capital540,919483,170
Accumulated other comprehensive loss(379)(1,175)
Accumulated deficit(350,349)(297,150)
Total stockholders’ equity190,195184,849
Total liabilities and stockholders’ equity$ 256,919$ 256,067
Edward M. Kaye
100
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.